| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 2,419 | |||
| General and administrative | 2,827 | |||
| Total operating loss | 5,246 | |||
| Interest income | 707 | |||
| Realized gain on sale of marketable securities, net | 0 | |||
| Gain (loss) on change in fair value of derivative instruments | 983 | |||
| Total non-operating income | 1,690 | |||
| Loss before income tax | -3,556 | |||
| Income tax provision | 0 | |||
| Net loss | -3,556 | |||
| Net loss per share, basic | -0.61 | |||
| Net loss per share, diluted | -0.61 | |||
| Weighted average number of shares outstanding, basic | 5,806,862 | |||
| Weighted average number of shares outstanding, diluted | 5,806,862 | |||
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)